Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys

Journal of Immunology

Volumn 168, Issue 4, 2002, Pages 1847-1853

  Santra, Sampa ^a   Schmitz, Jörn E ^a   Kuroda, Marcelo J ^a   Lifton, Michelle A ^a   Nickerson, Christine E ^a   Lord, Carol I ^a   Pal, Ranajit ^a   Franchini, Genoveffa ^a   Letvin, Norman L ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; RECOMBINANT CANARYPOX VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INFECTION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIREMIA; VIRUS REPLICATION;

EID: 0037083309     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.4.1847     Document Type: Article

References (40)

1. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
2. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
3. + lymphocyte response in acutely infected rhesus monkeys
4. + T cells in HIV-infected progressors and long-term nonprogressors
5. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
6. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
7. + lymphocytes
8. + T cell depletion in simian immunodeficiency virus-infected macaques
9. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
10. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocye responses and control viral replication after pathogenic SIV infection
11. Progress in the development of an HIV-1 vaccine
12. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120. HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
13. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
14. A primeboost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI): The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA
15. The safety and use of canarypox vectored vaccines
16. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
17. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicuting, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
18. + cytotoxic activity after receipt of envelope vaccines
19. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation
20. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccines
21. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
22. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
23. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus
24. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompafibility complex class I-peptide complex
25. Definition of an epitope and MHC class I molecule recognized by gagspecific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys
26. + cytotoxic T lymphocytes specific for dominant and subdominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys
27. mac251: Dependence of route of challenge exposure
28. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses
29. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases
30. HTLV-III, LAV, ARV are variants of same AIDS virus
31. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology
32. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) gag-pol primes for an anamnestic gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
33. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay SIV-induced immunodeficiency
34. + cytotoxic T lymphocytes
35. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by major histocompatibility complex class I/peptide tetramer
36. + T-cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen
37. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
38. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice
39. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection
40. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys